STRYKER CORP
Government Contracts & Awards
NATIONWIDE HEALTHCARE SOLUTIONS, LLC: $16.9M Department of Health and Human Services Contract
$16,911,173Proprietary Tech & Patents
No patents found in our USPTO sample (a narrow, keyword-clustered feed of recent grants in strategic tech sectors — not a comprehensive patent database).
Form D Funding
No recent SEC Form D filings found.
Market Intelligence & News
Stryker (NYSE:SYK) Slips After Q2 Revenue Miss Overshadows Earnings Beat
Stryker Q2 revenue slightly missed estimates but EPS beat; stock fell 9% after-hours amid cyber incident concerns and cautious guidance.
Stryker (NYSE:SYK) Posts Q2 CY2026 Sales In Line With Estimates But Stock Drops
Medical technology company Stryker (NYSE:SYK) met Wall Street’s revenue expectations in Q2 CY2026, with sales up 9.4% year on year to $6.59 billion. Its non-GAAP profit of $3.69 per share was 5.8% above analysts’ consensus estimates.
Stryker reports second quarter 2026 operating results
Portage, Michigan, July 30, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) reported operating results for the second quarter of 2026: Second Quarter Results Reported net sales increased 9.4% to $6.6 billionOrganic net sales increased 9.0%Reported operating income margin of 25.2%Adjusted operating income margin(1) increased 170 bps to 27.4%Reported EPS increased 44.1% to $3.30Adjusted EPS(1) increased 17.9% to $3.69 Second Quarter Net Sales Growth Overview Reported Foreign Currency Exchange Constant
Stryker Raises FY2026 Adj EPS Guidance from $14.90-$15.10 to $14.95-$15.10 vs $14.97 Est
Stryker (NYSE:SYK) raises FY2026 Adj EPS guidance from $14.90-$15.10 to $14.95-$15.10 vs $14.97 analyst estimate..
Correction: Stryker Q2 Adj. EPS $3.69 Beats $3.49 Estimate, Sales $6.589B Beat $6.579B Estimate
Stryker (NYSE:SYK) reported quarterly earnings of $3.69 per share which beat the analyst consensus estimate of $3.49 by 5.73 percent. This is a 17.89 percent increase over earnings of $3.13 per share from the same
Stryker (SYK) Launches Mako RPS To Bring Robotic Knee Surgery To More Surgeons
Stryker has introduced Mako RPS, a robotic handheld system for total knee replacement, expanding its Mako robotics portfolio. The launch extends robotic assistance to a wider range of orthopaedic procedures and care settings. The development highlights Stryker's focus on robotic-assisted surgery and surgeon flexibility in knee replacement. Stryker, traded as NYSE:SYK, is drawing attention with the launch of Mako RPS alongside a share price of $336.74. The stock is up 5.5% over the past week...
Exploring Analyst Estimates for Stryker (SYK) Q2 Earnings, Beyond Revenue and EPS
Besides Wall Street's top-and-bottom-line estimates for Stryker (SYK), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2026.
Stryker's Q2 Results Likely to Reflect Recovery of Q1 Deferred Orders
SYK heads into Q2 with robotic surgery momentum, deferred revenue recovery and strong procedure demand as investors watch for earnings and margin trends.
Comprehensive Nerve Repair Biomaterials Market Report Published, Profiles Medtronic, Stryker, Boston Scientific, and 20 Other Key Players
Opportunities in the nerve repair biomaterials market include advancements in regenerative medicine, rising demand for minimally invasive procedures, and smart biomaterials integration. Growth is driven by increased traumatic brain injuries, aging populations, and regional expansion, especially in Asia-Pacific. Nerve Repair Biomaterials Market Nerve Repair Biomaterials Market Dublin, July 13, 2026 (GLOBE NEWSWIRE) -- The "Nerve Repair Biomaterials Market Report 2026" has been added to ResearchAn
Stryker: The Market Is Overreacting To One Disrupted Quarter
Stryker (SYK) buy rating after a rare Q1 miss from a temporary cyber disruption. Full-year guidance holds; demand strong.
Congressional Trades in $SYK
Insider Trades (Form 4)
King Debra
Fletcher Robert S
Fink M Kathryn
Fletcher Robert S
Key People
Fletcher Robert S
VP, Chief Legal Officer
Political Giving
No disclosed PAC contributions found for this entity.
Factual Connections
Connections to other companies, executives, and politicians — sourced from disclosed trades, shared officers/directors, and public filings — are a Pro/Alpha feature.
Upgrade to Pro